IP Library Granted Patent US 11,273,141
Granted Patent B2
US 11,273,141 · App. 17/323,781 · Granted Mar 15, 2022

Low-dose carbachol compositions and methods for treatment of night vision disturbance

Inventors: Jack Martin Lipman (West Milford, NJ); Tushar Hingorani (Bridgewater, NJ); Kumaresh Soppimath (Skillman, NJ)
Assignee: VYLUMA INC.
A61K31/325A61K9/0048A61K9/08A61K47/02A61K47/186A61K47/38
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,273,141
App. No.
17/323,781
Granted
Mar 15, 2022
Kind
B2
Abstract

Ophthalmic formulations for acute and transient treatment of night vision disturbance syndrome (NVD) are presented. Preferred formulations comprise carbachol at very low concentrations that were demonstrated to unexpectedly provide an acute and transient therapeutic effect for a desirable magnitude and period of time.

Claims (14)

1. A method of acute and transient treatment of night vision disturbance in an individual, comprising:

topically administering a carbachol composition to an eye of an individual to reduce pupillary diameter by about 2 mm;

wherein the carbachol is present in the composition in an amount of equal or less than about 0.75%;

wherein the carbachol composition further comprises benzalkonium chloride in an amount of about 0.02%; and

wherein the carbachol composition has a pH of between about 6.5 and about 7.0 and a viscosity of between about 170 cP to about 220 cP.

2. The method of claim 1 , wherein the carbachol is present in the composition in an amount of equal or less than about 0.50%.

3. The method of claim 1 , wherein the carbachol is present in the composition in an amount of between about 0.25% and about 0.50%.

4. The method of claim 1 , wherein the carbachol composition has a pH of about 7.0 and a viscosity of between about 180 cP to about 190 cP.

5. The method of claim 1 , wherein a miotic effect of the composition is equal or less than 30% reduction in pupillary diameter.

6. The method of claim 1 , wherein the treatment reduces at least one of glare, starburst, halo, and double vision.

7. The method of claim 1 , wherein the composition further comprises a borate buffer and/or sodium chloride as tonicity agent.

8. The method of claim 1 , wherein the individual has not undergone refractive surgery.

9. The method of claim 1 , wherein the acute and transient treatment has a duration of equal or less than 3 hours at a reduction of pupillary diameter of about 2 mm.

10. The method of claim 1 , wherein the acute and transient treatment is an on-demand and non-curative treatment.

Assignments (5)
SECURITY INTEREST Recorded May 9, 2023
From: OXFORD FINANCE LLC
To: NOVAQUEST CO-INVESTMENT FUND X, L.P.
Reel/Frame 063588/0122 →
SECURITY INTEREST Recorded Jan 18, 2023
From: VYLUMA INC
To: OXFORD FINANCE LLC
Reel/Frame 062405/0266 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVE PROPERTY NUMBERS PREVIOUSLY RECORDED AT REEL: 057183 FRAME: 0825. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Aug 18, 2021
From: NEVAKAR INC.
To: NEVAKAR INJECTABLES INC.
Reel/Frame 057251/0432 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 12, 2021
From: NEVAKAR INC.
To: VYLUMA INC.
Reel/Frame 057163/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 18, 2021
From: LIPMAN, JACK MARTIN; HINGORANI, TUSHAR; SOPPIMATH, KUMARESH
To: NEVAKAR INC.
Reel/Frame 056278/0948 →